Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD3514 是一种口服雄激素受体下调剂(Ki :2.2 μM),能够减少 AR 蛋白表达。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 285 | 现货 | ||
5 mg | ¥ 624 | 现货 | ||
10 mg | ¥ 980 | 现货 | ||
25 mg | ¥ 1,934 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 713 | 现货 |
产品描述 | AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.Phase 1. |
靶点活性 | Androgen receptor:2.2 μM(Ki) |
体外活性 | AZD3514 binds to the AR ligand binding domain and has selectivity for binding to AR over other nuclear hormone receptors. In vitro AZD3514 inhibits cell growth in prostate cancer cells expressing wild-type (VCaP) and mutated (T877A) AR (LNCaP), but is inactive in AR-negative prostate cancer cells. AZD3514 causes a rapid reduction in PSA synthesis in vitro; with a significant decrease in PSA mRNA being evident in LNCaP cells within 2-3 h of compound treatment. AZD3514 inhibits an androgen-induced translocation of AR from the cytoplasm to the nucleus within a comparable time-frame in LNCaP cells and U2OS AR-transfected cells. AZD3514 treatment also reduces AR protein in LNCaP cells maintained in steroid-depleted conditions; an effect which is evident within 6-8 h, and maximal at 18-24 h. The ability to down-regulate AR under such conditions differentiates AZD3514 from the AR antagonists bicalutamide and Enzalutamide, which do not reduce AR protein levels. [2] |
体内活性 | Oral administration of AZD3514 (100 mg/kg once-daily for 7 days) significantly inhibits testosterone-induced growth of sexual accessory organs. The mode of action of AZD3514 is associated with loss of AR function. Administration of AZD3514 (100 mg/kg/day orally) for 3 days to Copenhagen rats bearing R3327H Dunning prostate tumours, indicates that AZD3514 treatment also reduces tumour AR in vivo. [2] |
分子量 | 519.56 |
分子式 | C25H32F3N7O2 |
CAS No. | 1240299-33-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (179 mM)
Ethanol: 93 mg/mL (179 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.9247 mL | 9.6235 mL | 19.2471 mL | 48.1176 mL |
5 mM | 0.3849 mL | 1.9247 mL | 3.8494 mL | 9.6235 mL | |
10 mM | 0.1925 mL | 0.9624 mL | 1.9247 mL | 4.8118 mL | |
20 mM | 0.0962 mL | 0.4812 mL | 0.9624 mL | 2.4059 mL | |
50 mM | 0.0385 mL | 0.1925 mL | 0.3849 mL | 0.9624 mL | |
100 mM | 0.0192 mL | 0.0962 mL | 0.1925 mL | 0.4812 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD3514 1240299-33-5 Endocrinology/Hormones Androgen Receptor selective anti proliferation LAPC4 Inhibitor oral AZD-3514 rat AR protein prostate cancer inhibit anti tumor AZD 3514 LNCaP inhibitor